RASGRP1 is a guanine-nucleotide-exchange factor that is involved in lymphocyte development and function 1 . The catalytic region of RASGRP1 consists of a RAS exchange motif and a CDC25 domain. RASGRP1 contains two atypical calcium-binding EF hands, a C1 diacylglycerol (DAG)-binding domain and a protein kinase C phosphorylation site that is necessary for activation of the protein 2 . Although the protein has high expression in lymphoid cells, its role is best studied in T cells following activation of the TCR 2 . Following increased DAG expression and/or phosphorylation by protein kinase C, RASGRP1 translocates to the membrane and converts the small GTPase RAS from an inactive GDP-bound to an active GTP-bound state. This process mediates activation of the MAP-kinase (RAS-RAF-MEK-ERK) cascade 3 .
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Although RAS signaling is well known for its association with malignant transformation, RAS GTPases control a variety of cellular processes under physiological conditions, including cell growth, differentiation, apoptosis, neuronal activity and cell migration. There are three main RAS isoforms (K, H and N) that all share a conserved core GTPase domain but have distinct biological functions. Depending on the upstream stimulus, RASGRP1 can activate all three Ras isoforms 4 . Studies of Rasgrp1 −/− mice have revealed substantial defects in thymocyte development and function as a result of defective TCR-mediated ERK phosphorylation. Accordingly, Rasgrp1 −/− mice have considerably fewer CD4 + and CD8 + T cells compared with wild-type mice 5 .
Studies of patients with inborn errors of their immune system (primary immunodeficiency disorders) have considerably shaped the molecular understanding of key nodes of human immunity, sometimes revealing surprising differences between patients and mouse models with deficiency in corresponding gene products [6] [7] [8] . In humans, the subgroup of quantitative or qualitative defects of T lymphocytes that result in combined immunodeficiencies comprise a heterogeneous subgroup of primary immunodeficiencies 9, 10 . Often, these defects are associated with primary or secondary B cell defects 11, 12 . Despite some heterogeneity, impairment of adaptive immunity in these diseases increases susceptibility to recurrent, earlyonset and severe infections with a variety of pathogens, including viruses, bacteria, fungi and parasites 9 .
We found that deficiency in human RASGRP1, a major regulator of RAS signaling in T lymphocytes, resulted in a previously unknown primary immunodeficiency disease. Our findings indicate a major role for RASGRP1 in immune cell signaling and function in T cells, B cells and NK cells. We also decipher a previously unknown role for RASGRP1 in the dynamic regulation of the cytoskeleton and identify lenalidomide as a potential treatment option for this immunodeficiency.
RESULTS

Identification of human RASGRP1 deficiency
We studied a 12-year-old index patient of healthy consanguineous parents (Fig. 1a) . Three older siblings of the patient (II/1, II/3 and II/4; Fig. 1a ) died in the first 2 years of life, possibly as a result of immunodeficiency-related complications. However, no material from these siblings was available for further genetic testing. The index patient presented with recurrent infections, including multiple episodes of pneumonia that resulted in bronchiectasis and collapse of the right upper pulmonary lobe (Fig. 1b) . Over time, severe failure to thrive, with height and weight below the third percentile, as well as finger clubbing became evident (data not shown). At the age of 12 years, after another episode of pneumonia, monthly intravenous immunoglobulin therapy was started. Prophylactic antibiotic therapy was recommended, which the patient did not use regularly. Further episodes of pneumonia and herpetic lesions necessitated hospitalization. Serial immunological analyses revealed normal numbers of total lymphocytes, but a progressive decrease in the number of CD4 + T cells, an inverted ratio of CD4 + T cells to CD8 + T cells, an increased relative proportion of TCRγδ cells, and progressively decreasing B cell counts compared with healthy individuals (Fig. 1c and Supplementary Table 1) . Routine adenotomy was performed on this patient at the age of 15 and, unexpectedly, histology revealed a low-grade Epstein-Barr virus (EBV)-associated B cell lymphoma (Supplementary Fig. 1a) . Given the immunodeficiency-related complications and the development of lymphoma, chemotherapy was performed, followed by myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.
Given the known consanguinity in the family and the absence of clinical signs of immunodeficiency in either parent, paralleled by unremarkable leukocyte immunophenotyping (Supplementary Tables 2  and 3) , we suspected an autosomal-recessive disease trait. We performed homozygosity mapping and exome sequencing to identify the underlying genetic disease etiology. Although we detected no variants in genes previously associated with primary immunodeficiencies, we found a homozygous nonsense variant on Chr15: 38805097: G>A (hg19 build 137) (c. C726T, p. Arg246*) in RASGRP1 (Fig. 1d,e) . This variant has not been observed in heterozygous or homozygous form in several human genetic variation databases including the 1000 Genomes Project and the Exome Aggregation Consortium (ExAC) (Supplementary Tables 4 and 5a) . It was predicted to be highly damaging for the corresponding protein function, with a combined annotation-dependent depletion (CADD) score of 35 (Supplementary Table 5b ). The RASGRP1 gene has a negative residual variation intolerance score and is among the 11.77% most intolerant genes, indicative of the evolutionary conservation of RASGRP1. Accordingly, the number of 'observed' nonsense variants was significantly lower than the number of 'expected' nonsense variants (Supplementary Table 5b) . Of note, no other homozygous variants in RASGRP1 leading to premature stop codons or frameshift mutations have been observed with higher population frequencies (Supplementary Table 5a ). The variant showed perfect co-segregation with the disease under the assumption of autosomal-recessive inheritance, with both parents and all three available healthy siblings being heterozygous for the detected variant (Supplementary Fig. 1 ). In addition to the identified stop codon variant in RASGRP1, a variant in UROC1 (p.G313R), which encodes urocanase enzyme, segregated with the disease in the core family (data not shown). Biallelic loss-of-function mutations in this gene have been shown to cause urocanic aciduria, mental retardation and ataxia 13 . As we could not reconcile this variant with the immunodeficiency in our patient, we disregarded this gene as being causative of the immunological phenotype in the index patient.
To assess the effect of the variant in RASGRP1, we expressed wild-type or mutant streptavidin-hemagglutinin (Strep-HA)-tagged RASGRP1 in doxycycline-inducible HEK293T human embryonic kidney cells and observed markedly reduced expression of the truncated protein product (Fig. 1f) . Consistent with these observations, immunoblot analysis with an antibody to RASGRP1 (anti-RASGRP1) did not detect endogenous full-length RASGRP1 protein in cells from the patient (Fig. 1g) .
Profound multifaceted peripheral blood T cell defects
Mouse studies have identified RASGRP1 as a guanine-nucleotideexchange factor that acts as an essential activator of the RAS-RAF-MEK-ERK signaling in T cells; it thus serves as a major regulator of T cell development 14 , survival and proliferation 15 . Activation of RASGRP1 is dependent on DAG and occurs following activation of the signaling protein PLCγ1 in T cells 16 . RASGRP1 has high expression in all lymphoid cells and in a variety of other cell types 17 . However, so far the function of mouse RASGRP1 beyond its function in T cells has remained largely elusive (comparison, Supplementary Table 6 ). We performed detailed T cell immunophenotyping to characterize deficiency in human RASGRP1 and observed persistent CD4 + T cell lymphopenia together with an increase in the number of CD8 + T cells compared with healthy controls (Fig. 2a) . Evaluation of the distribution of TCRαβ T cells versus that of TCRγδ T cells revealed increased numbers of TCRγδ + CD8 + T cells compared to reference values (Supplementary Table 1 ). We further investigated the compartment of non-conventional T cells and observed reduced numbers of mucosal-associated invariant T cells (Supplementary Table 3) . Furthermore, the number of invariant NKT cells was very low, bordering on absent (Supplementary Tables 3 and 6, and Supplementary  Fig. 2) , reminiscent of studies of mice 18 . Although a prominent population expressing the TCR α-chain variable region 24 (V α 24) was detectable 19 , these cells expressed the surface markers CD8 and CD45RA (Supplementary Fig. 2a) , which suggested that they might belong to oligoclonally expanded and exhausted memory CD8 + T cells.
Both CD4 + T cells and CD8 + T cells from the patient exhibited an exhausted phenotype, as indicated by expansion of CCR7 − CD45RA + effector memory T cell populations, which represented up to 80% of CD8 + T cells (Fig. 2b,c, Supplementary Table 3 and Supplementary  Fig. 3 ). In the CD4 + T cell subset, the majority of cells were CD45RA − CXCR5 + (Fig. 2d) , suggestive of an increased frequency in peripheral blood follicular helper T cells compared with healthy controls 5, 20, 21 . In the CD4 + compartment of the patient, normal proportions of CD25 + FOXP3 + CD4 + regulatory T cells and recent thymic emigrants were present (Supplementary Table 3) .
Functionally, both RASGRP1-deficient CD4 + T cells and RASGRP1-deficient CD8 + T cells showed defective proliferation after stimulation with antibody to the TCR invariant chain CD3 (anti-CD3) and antibody 1 3 5 4 VOLUME 17 NUMBER 12 DECEMBER 2016 nature immunology A r t i c l e s to the costimulatory molecule CD28 (anti-CD28) ( Fig. 2e and Supplementary Fig. 3 ), accompanied by impaired expression of the activation markers CD25 and CD69 (Fig. 2f) . Defective T cell proliferation was recapitulated in Jurkat human T cells with doxycycline-inducible short hairpin RNA-based knockdown of RASGRP1 (shRASGRP1) (Supplementary Fig. 2b ). In addition, proliferation assays using thymidine incorporation also showed defective cellular proliferation after nonspecific stimulation with various mitogens (Supplementary Fig. 2c) . Consistent with the above-mentioned proliferation defects, TCR V β spectratyping of patient peripheral blood T cells revealed a restricted TCR repertoire ( Fig. 2g and Supplementary Fig. 2d ). CD8 + cytotoxic T cell populations obtained from the patient and expanded ex vivo showed increased expression of perforin and granzyme B compared to healthy donors (Fig. 2h) , as well as defective killing of targets cells following activation with the monoclonal antibody against CD3 (OKT-3) (Fig. 2i) .
Published studies have shown that RASGRP1 is critical for TCRinduced signal transduction in mouse T cells 5, 16 . Here we sought to investigate the functional consequences of RASGRP1 deficiency on the activation of human T cells. In both inducible shRASGRP1-Jurkat cells and in a patient T cell line, immortalized using human telomerase reverse transcriptase (hTERT) we did not observe defects in initial TCR signaling events upstream of RASGRP1, including intercellular adhesion molecule 1 (ICAM1) ring formation, exclusion from the central supramolecular activation complex (cSMAC), or calcium flux ( Fig. 2j and Supplementary Fig. 2e-g ). Thus, we focused on potential signaling defects downstream of RASGRP1 in populations of primary peripheral blood mononuclear cells (PBMCs) obtained from patient and expanded ex vivo using anti-CD3 and anti-CD28. Cells were serum-and antibodystarved and re-stimulated with anti-CD3 and anti-CD28. We observed reduced, but not absent, phosphorylation of ERK1/2 (at Thr202 and Tyr204) in RASGRP1-deficient cells compared to healthy donor expanded T cells (Fig. 2k,l and Supplementary Fig. 2h ). Transient transfection of the cells with vector encoding wild-type RASGRP1 normalized impaired activation of ERK in the patient's CD8 + T cells (Fig. 2m) .
Deficient B cell activation and proliferation
Studies of the role of RASGRP1 in mouse B cells have remained contradictory 22, 23 . We performed detailed immunophenotypic analysis of the patient's B cell subsets and observed decreased proportions of memory B cells (CD19 + CD27 + ) and increased proportions of both transitional B cells and CD21 lo B cells, the latter of which consituted up to 20% of all CD19 + B cells, compared to healthy donor B cell subsets (Fig. 3a,b and Supplementary Fig. 3 ). The concentrations of total immunoglobulin G (IgG) and IgM were normal in the patient, but IgA concentrations were elevated (Supplementary Table 1 ). Although findings from mouse studies have suggested a role for RASGRP1 in the development of autoimmunity 22 and genome-wide association studies have identified an association of single-nucleotide variants in the gene encoding RASGRP1 with systemic lupus erythematodes 24 , no clinical signs of autoimmunity were apparent, consistent with the absence of detectable autoantibodies (Supplementary Table 7 ). However, we observed insufficient vaccination responses, including absent antibodies to hepatitis B surface antigen and decreased pneumococcusspecific antibodies following vaccination (data not shown).
To assess B cell function, we stimulated the patient's PBMCs with antibody to the costimulatory receptor CD40 and interleukin 4 (IL-4) 25 . 
A r t i c l e s
The patient's B cells, compared to healthy donor B cells, showed reduced upregulation of expression of the activation markers CD86, CD25, CD95 and CD69 (Fig. 3c) that resulted in decreased B cell proliferation (Fig. 3d) and reduced class-switch recombination following stimulation (Fig. 3e) . The observed defects could not be reversed by the addition of the mature B cell survival factor BAFF (Fig. 3f) , which suggested that self-reactive transitional B cells were absent from the PBMC compartment 26 .
Both quantitative defects and qualitative defects in B cells in patients with inherited deficiencies of T cells result from either an intrinsic B cell defect (primary defect) or deficient co-stimulation 11, 12 . To assess our hypothesis of a B cell-intrinsic phenotype, we evaluated B cell antigen receptor (BCR) signaling in EBV-transformed B cell lines from the patient. The EBV-immortalized B cells showed reduced activation of the MAPK pathway following IgM stimulation, similar to the T cell defects that we observed (Fig. 3g) . Defective ERK A r t i c l e s phosphorylation in patient B cells was reversed after lentiviral transduction of wild-type RASGRP1 (Fig. 3h) . Collectively, the patient's B cells showed defective MAPK activation, with defective BCR signaling resulting in reduced proliferation and class switching.
RASGRP1 deficiency causes impaired NK-cell cytotoxicity
Mouse studies have not yet addressed the role of RASGRP1 in NK cells, to the best of our knowledge. We observed unaltered numbers of the patient's NK cells with normal CD56 dim and CD56 bright subset distributions (Supplementary Table 1 ). However, the CD56 bright NK cells had high expression of intracellular IL-5 ( Supplementary Fig. 4a ). These data might suggest that there is a developmental bias toward the production of T helper type 2 cytokines at an intermediate differentiation state, as production of these cytokines is lost following terminal differentiation 27 . Despite having high protein expression levels of intracellular granzyme B and perforin (Fig. 4a) , the patient's NK cells exhibited severely impaired cytolytic function (Fig. 4b) . This impairment was associated with defective formation of a mature NK cell immunological synapse in CRISPR/Cas9-edited NK-92 cell lines deficient in RASGRP1 (sgRASGRP1) (Fig. 4c) with decreased F-actin accumulation, increased distance from the microtubule-organizing center (MTOC) to the synapse and impaired granule convergence (Fig. 4d-f) , consistent with impaired formation of the NK cell immunological synapse in primary cells from the patient (Supplementary Fig. 4b ).
Proteomics links RASGRP1 to cytoplasmic dynein
The patient's CD8 + T cells displayed normal expression of ICAM1 and did not show any defects in ICAM1 ring formation or exclusion from the central supramolecular activation complex following TCR stimulation (Supplementary Fig. 2f ), which suggested that the cells retained the required elements for formation of the immunological synapse. In addition, the patient's NK cells showed normal expression of NK cell-activating receptors, as well as similar levels of granzyme B and perforin protein expression compared to healthy donor NK cells (Fig. 4a) . However, we observed an unusual combination of defective granule convergence together with defects in the accumulation of F actin in both the patient's NK cells and sgRASGRP1 NK-92 cells. Assuming a similar role for MAPK activation in actin polymerization in both T cells and NK cells 28 , we hypothesized that the defect in granule convergence might be linked to an as-yetunknown interaction partner. Thus, we performed tandem affinity purification of RASGRP1 tagged at the amino terminus with Strep-HA plus subsequent mass-spectrometry analysis of bound interactors in HEK293T cells and Jurkat T cells (Fig. 4g) . In both HEK293T cells and Jurkat T cells which were engineered for doxycycline-inducible RASGRP1 expression, the dynein light chain DYNLL1 was one of the top-ranking interacting proteins according to both SAINT and FC-scoring (Fig. 4g) . Notably, published studies of mice and rats have reported binding of RASGRP3, but not of RASGRP1, to DYNLL1 (ref. 29) . Such cross-species differences might be explained by the fact only human RASGRP1 contains a binding motif similar to that of mouse RASGRP3 (ref. 30) (Fig. 4h) . Co-immunoprecipitation of RASGRP1 tagged at the amino terminus with Strep-HA confirmed the interaction of RASGRP1 with endogenous DYNLL1 in both Jurkat T cells and HEK293T cells (Fig. 4i, Supplementary Table 8a,b and Supplementary Fig. 4d) . Substitution of the assumed DYNLL1-binding motif with alanine residues resulted in abrogation of the binding of DYNLL1 (Fig. 4i) , which confirming the critical role of this motif in the RASGRP1-DYNLL1 interaction. Cytoplasmic dynein can mediate retrograde transport over the microtubule cytoskeleton toward the MTOC in T cells, which results in centrosome polarization following TCR activation 31 . In NK cells, dynein-driven transport of lytic granules along microtubules is required for convergence to the MTOC preceding formation of the immunological synapse 32 . Visualization of sgRASGRP1 NK cells by video microscopy revealed markedly defective granule motility (Fig. 4j,k) . Consistent with a putative role for RASGRP1 in regulating the microtubule cytoskeleton, accumulation of dynein before centrosome polarization has been shown to depend on the RASGRP1 activator DAG 33 . Moreover, lytic granule convergence occurs rapidly after target-cell engagement and is independent of actin dynamics 32 . Thus, RASGRP1 deficiency markedly affects NK cell cytotoxicity by impairing both actin polymerization and the convergence of lytic granules to the MTOC, which is possibly explained by an abrogated interaction with DYNLL1. 
A r t i c l e s
Reversal of cellular defects by lenalidomide Apart from NK-cell cytotoxicity, microtubules and actin also depend on precisely coordinated interactions to establish cell polarity 34 and the coordinated cell migration that is essential for lymphocyte function 34 . To visualize cytoskeletal dynamics and cell migration in primary cells from the patient, we transiently transfected CD8 + T cells with the actin marker Lifeact TM . We observed significantly slower actin turnover in RASGRP1-deficient CD8 + T cells than in CD8 + T cells from healthy donors (Fig. 5a,b) . To assess whether slow actin turnover would also 'translate' into a low cell-migration speed, we performed cell-migration assays with CD8 + T cells stimulated with the chemokine CXCL12 on ICAM-1-coated plates. Indeed, RASGRP1-deficient cells migrated at lower speeds than did CD8 + T cells from healthy donors (Fig. 5c) .
RASGRP1-deficient mouse mast cells display decreased RhoA activity 35 . We found that levels of active RhoA were markedly lower in the patient's T cells following CXCL12 stimulation compared with healthy donor T cells, whereas total RhoA levels differed only mildly ( Supplementary Fig. 5 ). Thus, we hypothesized that activation of RhoA signaling might reverse the migration defect of RASGRP1-deficient CD8 + T cells. Indeed, the known RhoA activator nocodazole normalized the observed migration defect (Fig. 5d) . However, as nocodazole is not amenable for clinical use, we sought to identify an alternative compound that could induce similar functional effects. In patients with chronic lymphocytic leukemia, T cells exhibit an exhausted (immunodeficient) phenotype that is similar to that of the RASGRP1-deficient patient 36, 37 . The thalidomide-derived drug lenalidomide can modulate the activity of key transcription factors that are important for restoring T cell function, which results in increased RhoA activity 38 . Indeed, treatment with lenalidomide significantly increased cell velocity and thus normalized the overt migration defect observed in RASGRP1-deficient PBMCs (Fig. 5e) ; thus, this might represent a potential treatment option for RASGRP1-deficient patients. Consistent with the published positive effect of lenalidomide on IL-2 secretion 39 , we observed increased CD25 expression in T cells following lenalidomide treatment (Fig. 5f ). Given that lenalidomide modifies multiple targets of the Cullin-E3 ligase complex by binding to its intracellular target cereblon, we aimed to investigate whether the effect of lenalidomide on the cellular phenotype could be linked to normalization of RhoA signaling. In CD8 + T cells from healthy control donors, stimulation with CXCL12 activated RhoA, as detected with an antibody specific for the GTP-bound state of RhoA (Fig. 5g,h ). In contrast, CD8 + T cells from the RASGRP1-deficient patient failed to activate RhoA following stimulation with CXCL12 (Fig. 5g,h) . Notably, treatment of the patient's CD8 + T cells with additional lenalidomide restored active RhoA to amounts comparable to those measured in the control CD8 + T cells (Fig. 5g,h ).
DISCUSSION
We identified human RASGRP1 deficiency as a previously unknown primary immunodeficiency with notable defects in the lymphoid compartment that were amenable to partial reversal with lenalidomide. Although our study was performed on a pedigree with a single affected patient, our results demonstrated that the loss of RASGRP1 caused the phenotype, consistent with outlined criteria as published 40 : the patient's candidate genotype was monogenic and did not occur in subjects without the clinical phenotype; we found that the detected mutation caused the absence of full-length RASGRP1 protein and reduced ERK phosphorylation; we observed restoration of the defective phosphorylation of ERK following expression of wildtype RASGRP1 in the patient's cells; and shRNA and CRISPR-based studies of Jurkat cells and NK-92 cell lines reproduced the phenotype observed in primary cells from the patient. The phenotype of human RASGRP1 deficiency differs substantially from previously described mouse models 5, 22 and suggests a previously unknown role for RASGRP1 in cellular responses beyond TCR signaling. Although RASGRP1-deficient mice exhibit decreased numbers of both CD4 + and CD8 + single-positive thymocytes 5 , the patient's immunological phenotype showed an inverted ratio of CD4 + T cells to CD8 + T cells with population expansion of exhausted effector memory cells, consistent with a partial T cell defect 9 . Partial T cell defects are often associated with autoimmunity 9 . The role of RASGRP1 in autoimmunity has remained controversial. Both RASGRP1-deficient mice 22 with an autoreactive BCR and Rasgrp1 −/− mice overexpressing a truncated form of RASGRP1 that lacks the carboxy-terminal tail domain 41 develop a lymphoproliferative disorder with features reminiscent of human systemic lupus erythematosus. We did not observe overt autoimmunity in human RASGRP1 deficiency. Future studies, including more RASGRP1-deficient subjects, will enable delineation of the full phenotypic spectrum of human RASGRP1 deficiency. The role of RASGRP1 in NK cells has not been addressed in detail in mouse models. NK cells are innate immune cells best known for their ability to mediate cytotoxicity after the ligation of germlineencoded activation receptors 42 . A variety of human primary immunodeficiencies are associated with defective accumulation of actin at the immunological synapse, particularly actin-polymerization deficiencies such as Wiskott-Aldrich syndrome 43 or deficiency in the actin regulators WIP 44 or DOCK8 (ref. 45) . However, the combination of defective polymerization of actin, together with the considerable granule-convergence defect seen in cells from the RASGRP-deficient patient has not been seen in human immunodeficiencies before, to our knowledge.
Accumulation of dynein before centrosome polarization in lymphocytes depends on the known RASGRP1 activator DAG 46 . Evidence has revealed a RAS-binding domain in the dynein intermediate chain that probably mediates activation of the complex 47 . Our discovery of an interaction between human RASGRP1 and cytosolic DYNLL1 provides evidence that RASGRP1 mediates granule convergence following activation, a dynein-dependent process 32 . To our knowledge, RASGRP1 deficiency represents the first association of impaired dynein function with a human primary immunodeficiency. Of note, several viral proteins, including the HIV-1 integrase, interact with DYNLL1, and their interaction has been shown to be involved in efficient reverse transcription of HIV-1 (ref. 48) .
Our study has also identified a targeted treatment strategy with lenalidomide, providing proof-of-concept for such approaches in primary (and potentially secondary) immunodeficiencies with aberrant cytoskeletal dynamics. Thus far, the thalidomide derivative lenalidomide has been approved for various lymphoid malignancies, such as multiple myeloma 37 and chronic lymphocytic leukemia 36 . In these diseases, T cells are in a state of pseudo-exhaustion and show defects in activation, proliferation and cytotoxicity 49 , similar to those observed in RASGRP1 deficiency. The action of lenalidomide has been linked to cereblon which, together with the scaffolding protein CUL4 and the catalytic subunit ROC1, forms the E3 ubiquitin ligase cereblon-CRL4 complex that mediates degradation of the transcription factors Ikaros and Aiolos and may alter other targets of the E3 ubiquitin ligase 38 . These processes result in, among other effects, the upregulation of RhoA activity, which might be the factor responsible for the rescue of RASGRP1-deficient lymphocytes 36 ; we found that treatment with lenalidomide significantly increased RhoA activity in patient CD8 + T cells. In sum, we have identified RASGRP1 deficiency as a previously unknown type of partial T cell defect, which revealed a previously unknown link between RAS signaling and cytosolic dynein dynamics and which was amenable to improvement following RhoA activation and lenalidomide treatment.
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Methods and any associated references are available in the online version of the paper. 
